A citation-based method for searching scientific literature

Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard, Kezhen L Tang, C Janneke van der Woude, Paul Rutgeerts. N Engl J Med 2010
Times Cited: 2115







List of co-cited articles
675 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Remo Panaccione, Subrata Ghosh, Stephen Middleton, Juan R Márquez, Boyd B Scott, Laurence Flint, Hubert J F van Hoogstraten, Annie C Chen, Hanzhe Zheng, Silvio Danese,[...]. Gastroenterology 2014
561
21

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri,[...]. Lancet Gastroenterol Hepatol 2019
235
20

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao,[...]. Lancet 2002
17

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Joana Torres, Stefanos Bonovas, Glen Doherty, Torsten Kucharzik, Javier P Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager,[...]. J Crohns Colitis 2020
297
17

Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler,[...]. N Engl J Med 2013
16

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
821
15

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
Fernando Gomollón, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James O Lindsay, Laurent Peyrin-Biroulet, Garret J Cullen, Marco Daperno, Torsten Kucharzik,[...]. J Crohns Colitis 2017
13

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Nilesh Chande, Petrease H Patton, David J Tsoulis, Benson S Thomas, John K MacDonald. Cochrane Database Syst Rev 2015
124
12

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
12

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D Kent,[...]. Gastroenterology 2007
12

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
S R Targan, S B Hanauer, S J van Deventer, L Mayer, D H Present, T Braakman, K L DeWoody, T F Schaible, P J Rutgeerts. N Engl J Med 1997
11

Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
Marco Daperno, Geert D'Haens, Gert Van Assche, Filip Baert, Philippe Bulois, Vincent Maunoury, Raffaello Sostegni, Rodolfo Rocca, Angelo Pera, Annemie Gevers,[...]. Gastrointest Endosc 2004
897
11

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Stephen B Hanauer, William J Sandborn, Paul Rutgeerts, Richard N Fedorak, Milan Lukas, Donald MacIntosh, Remo Panaccione, Douglas Wolf, Paul Pollack. Gastroenterology 2006
11

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Jean-Frédéric Colombel, Omoniyi J Adedokun, Christopher Gasink, Long-Long Gao, Freddy J Cornillie, Geert R D'Haens, Paul J Rutgeerts, Walter Reinisch, William J Sandborn, Stephen B Hanauer. Clin Gastroenterol Hepatol 2019
72
15

Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts, William J Sandborn, Brian G Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B Hanauer, Gary R Lichtenstein,[...]. N Engl J Med 2005
11

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L Peyrin-Biroulet, W Sandborn, B E Sands, W Reinisch, W Bemelman, R V Bryant, G D'Haens, I Dotan, M Dubinsky, B Feagan,[...]. Am J Gastroenterol 2015
10

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Magali Lemaitre, Julien Kirchgesner, Annie Rudnichi, Fabrice Carrat, Mahmoud Zureik, Franck Carbonnel, Rosemary Dray-Spira. JAMA 2017
260
10

Crohn's disease.
Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet. Lancet 2017
780
10

ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Gary R Lichtenstein, Edward V Loftus, Kim L Isaacs, Miguel D Regueiro, Lauren B Gerson, Bruce E Sands. Am J Gastroenterol 2018
483
9

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.
Joseph D Feuerstein, Geoffrey C Nguyen, Sonia S Kupfer, Yngve Falck-Ytter, Siddharth Singh. Gastroenterology 2017
295
9

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
Marcus Harbord, Rami Eliakim, Dominik Bettenworth, Konstantinos Karmiris, Konstantinos Katsanos, Uri Kopylov, Torsten Kucharzik, Tamás Molnár, Tim Raine, Shaji Sebastian,[...]. J Crohns Colitis 2017
579
9

HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Aleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, Graham A Heap, Daniel L Rice, Mark Reppell, Claire M Bewshea, Neil Chanchlani, Gareth J Walker, Mandy H Perry,[...]. Gastroenterology 2020
122
9



Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Niels Vande Casteele, Marc Ferrante, Gert Van Assche, Vera Ballet, Griet Compernolle, Kristel Van Steen, Steven Simoens, Paul Rutgeerts, Ann Gils, Séverine Vermeire. Gastroenterology 2015
566
8

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Julien Kirchgesner, Magali Lemaitre, Fabrice Carrat, Mahmoud Zureik, Franck Carbonnel, Rosemary Dray-Spira. Gastroenterology 2018
248
8

Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
X Roblin, G Boschetti, N Williet, S Nancey, H Marotte, A Berger, J M Phelip, L Peyrin-Biroulet, J F Colombel, E Del Tedesco,[...]. Aliment Pharmacol Ther 2017
79
10

Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Glen S Hazlewood, Ali Rezaie, Meredith Borman, Remo Panaccione, Subrata Ghosh, Cynthia H Seow, Ellen Kuenzig, George Tomlinson, Corey A Siegel, Gil Y Melmed,[...]. Gastroenterology 2015
175
8

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu'Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger,[...]. Gut 2019
545
8

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukas, Filip Baert, Tomas Vaňásek, Ahmet Danalioglu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hébuterne,[...]. Lancet 2017
409
7

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Byong Duk Ye, Marina Pesegova, Olga Alexeeva, Marina Osipenko, Adi Lahat, Andriy Dorofeyev, Sigal Fishman, Olena Levchenko, Jae Hee Cheon, Maria Lia Scribano,[...]. Lancet 2019
93
7

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Paul Rutgeerts, Gert Van Assche, William J Sandborn, Douglas C Wolf, Karel Geboes, Jean-Frédéric Colombel, Walter Reinisch, Ashish Kumar, Andreas Lazar, Anne Camez,[...]. Gastroenterology 2012
408
7

Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.
Andres J Yarur, Maddie J Kubiliun, Frank Czul, Daniel A Sussman, Maria A Quintero, Anjali Jain, Katherine A Drake, Scott I Hauenstein, Steven Lockton, Amar R Deshpande,[...]. Clin Gastroenterol Hepatol 2015
119
7

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
Shomron Ben-Horin, Matti Waterman, Uri Kopylov, Miri Yavzori, Orit Picard, Ella Fudim, Halim Awadie, Batia Weiss, Yehuda Chowers. Clin Gastroenterol Hepatol 2013
233
7

Certolizumab pegol for the treatment of Crohn's disease.
William J Sandborn, Brian G Feagan, Simeon Stoinov, Pieter J Honiball, Paul Rutgeerts, David Mason, Ralph Bloomfield, Stefan Schreiber. N Engl J Med 2007
779
7

Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Xavier Roblin, Nicolas Williet, Gilles Boschetti, Jean-Marc Phelip, Emilie Del Tedesco, Anne-Emmanuelle Berger, Philippe Vedrines, Gerard Duru, Laurent Peyrin-Biroulet, Stéphane Nancey,[...]. Gut 2020
50
14

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
Takayuki Matsumoto, Satoshi Motoya, Kenji Watanabe, Tadakazu Hisamatsu, Hiroshi Nakase, Naoki Yoshimura, Tetsuya Ishida, Shingo Kato, Tomoo Nakagawa, Motohiro Esaki,[...]. J Crohns Colitis 2016
125
7

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
F M Ruemmele, G Veres, K L Kolho, A Griffiths, A Levine, J C Escher, J Amil Dias, A Barabino, C P Braegger, J Bronsky,[...]. J Crohns Colitis 2014
591
7

Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Amit Assa, Manar Matar, Dan Turner, Efrat Broide, Batia Weiss, Oren Ledder, Anat Guz-Mark, Firas Rinawi, Shlomi Cohen, Chani Topf-Olivestone,[...]. Gastroenterology 2019
97
7


Infliximab maintenance therapy for fistulizing Crohn's disease.
Bruce E Sands, Frank H Anderson, Charles N Bernstein, William Y Chey, Brian G Feagan, Richard N Fedorak, Michael A Kamm, Joshua R Korzenik, Bret A Lashner, Jane E Onken,[...]. N Engl J Med 2004
7

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.
Christian Maaser, Andreas Sturm, Stephan R Vavricka, Torsten Kucharzik, Gionata Fiorino, Vito Annese, Emma Calabrese, Daniel C Baumgart, Dominik Bettenworth, Paula Borralho Nunes,[...]. J Crohns Colitis 2019
439
6

Crohn's disease management after intestinal resection: a randomised trial.
Peter De Cruz, Michael A Kamm, Amy L Hamilton, Kathryn J Ritchie, Efrosinia O Krejany, Alexandra Gorelik, Danny Liew, Lani Prideaux, Ian C Lawrance, Jane M Andrews,[...]. Lancet 2015
325
6


3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.
Paolo Gionchetti, Axel Dignass, Silvio Danese, Fernando José Magro Dias, Gerhard Rogler, Péter Laszlo Lakatos, Michel Adamina, Sandro Ardizzone, Christianne J Buskens, Shaji Sebastian,[...]. J Crohns Colitis 2017
349
6

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Kristin K Jørgensen, Inge C Olsen, Guro L Goll, Merete Lorentzen, Nils Bolstad, Espen A Haavardsholm, Knut E A Lundin, Cato Mørk, Jørgen Jahnsen, Tore K Kvien. Lancet 2017
458
6

Crohn's disease.
Daniel C Baumgart, William J Sandborn. Lancet 2012
6

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Reena Khanna, Brian Bressler, Barrett G Levesque, Guangyong Zou, Larry W Stitt, Gordon R Greenberg, Remo Panaccione, Alain Bitton, Pierre Paré, Séverine Vermeire,[...]. Lancet 2015
273
6

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Filip Baert, Liesbeth Moortgat, Gert Van Assche, Philip Caenepeel, Philippe Vergauwe, Martine De Vos, Pieter Stokkers, Daniel Hommes, Paul Rutgeerts, Severine Vermeire,[...]. Gastroenterology 2010
616
6

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Ray K Boyapati, Joana Torres, Carolina Palmela, Claire E Parker, Orli M Silverberg, Sonam D Upadhyaya, Tran M Nguyen, Jean-Frédéric Colombel. Cochrane Database Syst Rev 2018
31
19


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.